Optical coherence tomography in the management of diabetic macular oedema.

Autor: Szeto SK; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China., Lai TY; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China., Vujosevic S; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy; Eye Clinic, IRCCS MultiMedica, Milan, Italy., Sun JK; Beetham Eye Institute, Harvard Medical School, Boston, USA., Sadda SR; Doheny Eye Institute, University of California Los Angeles, Los Angeles, USA., Tan G; Singapore Eye Research Institute, SingHealth Duke-National University of Singapore, Singapore., Sivaprasad S; NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK., Wong TY; Tsinghua Medicine, Tsinghua University, Beijing, China; Singapore Eye Research Institute, Singapore., Cheung CY; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China. Electronic address: carolcheung@cuhk.edu.hk.
Jazyk: angličtina
Zdroj: Progress in retinal and eye research [Prog Retin Eye Res] 2024 Jan; Vol. 98, pp. 101220. Date of Electronic Publication: 2023 Nov 07.
DOI: 10.1016/j.preteyeres.2023.101220
Abstrakt: Diabetic macular oedema (DMO) is the major cause of visual impairment in people with diabetes. Optical coherence tomography (OCT) is now the most widely used modality to assess presence and severity of DMO. DMO is currently broadly classified based on the involvement to the central 1 mm of the macula into non-centre or centre involved DMO (CI-DMO) and DMO can occur with or without visual acuity (VA) loss. This classification forms the basis of management strategies of DMO. Despite years of research on quantitative and qualitative DMO related features assessed by OCT, these do not fully inform physicians of the prognosis and severity of DMO relative to visual function. Having said that, recent research on novel OCT biomarkers development and re-defined classification of DMO show better correlation with visual function and treatment response. This review summarises the current evidence of the association of OCT biomarkers in DMO management and its potential clinical importance in predicting VA and anatomical treatment response. The review also discusses some future directions in this field, such as the use of artificial intelligence to quantify and monitor OCT biomarkers and retinal fluid and identify phenotypes of DMO, and the need for standardisation and classification of OCT biomarkers to use in future clinical trials and clinical practice settings as prognostic markers and secondary treatment outcome measures in the management of DMO.
(Copyright © 2023. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: